Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

PHASE3CompletedINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

November 30, 2014

Conditions
Diabetic Macular Edema
Interventions
DRUG

Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

PROCEDURE

Macular Laser Photocoagulation

Laser therapy

Trial Locations (51)

Unknown

Phoenix

Tucson

Arcadia

Beverly Hills

La Jolla

Mountain View

Oakland

Palm Desert

Sacramento

San Francisco

Santa Barbara

Torrance

Colorado Springs

Golden

New London

Fort Lauderdale

Fort Myers

Miami

Orlando

Winter Haven

Augusta

‘Aiea

Wichita

Portland

Baltimore

Boston

Missoula

Las Vegas

New Brunswick

Northfield

Teaneck

Lynbrook

Orchard Park

Rochester

Asheville

Charlotte

Raleigh

Portland

Kingston

Pittsburgh

Florence

West Columbia

Rapid City

Nashville

Abilene

Austin

Harlingen

Houston

San Antonio (2 Locations)

The Woodlands

Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY